Insider Selling: Gilead Sciences CFO Sells 10,400 Shares of Stock (GILD)
Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington unloaded 10,400 shares of the stock on the open market in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $83.98, for a total transaction of $873,392.00. The sale was disclosed in a filing with the SEC, which is available at this link.
Gilead Sciences (NASDAQ:GILD) traded up 1.98% during mid-day trading on Wednesday, hitting $86.98. 12,127,735 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $51.63 and a 1-year high of $85.49. The stock has a 50-day moving average of $81.40 and a 200-day moving average of $77.83. The company has a market cap of $133.6 billion and a price-to-earnings ratio of 31.59. Gilead Sciences also saw a large decrease in short interest during the month of June. As of June 13th, there was short interest totalling 92,230,036 shares, a decrease of 2.0% from the May 30th total of 94,135,575 shares. Based on an average daily trading volume, of 10,372,330 shares, the days-to-cover ratio is presently 8.9 days. Currently, 6.0% of the company’s shares are sold short.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.28 EPS for the current fiscal year.
A number of analysts have recently weighed in on GILD shares. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Monday. They now have a $75.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Finally, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $135.00 to $142.00 in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $94.91.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.